Comparable stake leader
BlackRock, Inc.
SEC ownership of BIOCRYST PHARMACEUTICALS INC
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000882796.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- BCRX on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
BlackRock, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
BlackRock, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000882796
- Issuer location
- Durham, NC
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of BIOCRYST PHARMACEUTICALS INC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
30 Jun 2026
13F
13D/G
3/4/5
Lead comparable stake: 8.4%
13D/G row: BlackRock, Inc.
Showing 1-8 of 50 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 8.4%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
8.4%
James E. Flynn
6.8%
RA CAPITAL MANAGEMENT, L.P.
6.2%
STATE STREET CORP
6%
VANGUARD CAPITAL MANAGEMENT LLC
5.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
Company
|
8.4%
from 13D/G
|
$238,930,360
23,893,036 shares
|
— | 30 Jun 2026 |
| James E. Flynn |
13D/G
Deerfield Mgmt, L.P.
|
6.8%
|
$109,278,420
14,341,000 shares
|
+$16,550,640 | 31 Dec 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
13F
Company
|
6.2%
|
$173,940,774
15,827,186 shares
|
+$5,769,750 | 30 Jun 2026 |
| STATE STREET CORP |
13D/G
13F
STATE STREET CORPORATION · Company
|
6%
|
$166,950,167
15,191,098 shares
|
+$32,780,291 | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
5.2%
|
$123,390,357
12,961,172 shares
|
$0 | 31 Mar 2026 |
| Avoro Capital Advisors LLC |
13D/G
|
4.2%
|
$71,514,000
8,700,000 shares
|
$0 | 31 Mar 2025 |
| Charles K. Gayer |
3/4/5
President and CCO
|
0.37%
|
$5,248,732
952,583 shares
|
— | 19 Dec 2025 |
| Alane P. Barnes |
3/4/5
Chief Legal Officer
|
0.16%
|
$3,822,706
400,703 shares
|
-$3,462,537 | 13 May 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$4,136,188.
Buys
$0
Insiders: 0
Sells
$4,136,188
Insiders: 4
Net
-$4,136,188
Shares: -487,876
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 487,876
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 273,613 | $0 | $2,573,857 | -$2,573,857 |
| 6-9 | 0 | 42,983 | $0 | $328,820 | -$328,820 |
| 9-12 | 0 | 171,280 | $0 | $1,233,511 | -$1,233,511 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 24 reporting-owner rows connected to BIOCRYST PHARMACEUTICALS INC. Open a relationship link for the CIK-to-CIK filing trail.
Rows
24
Largest Forms 3/4/5 holder
Jon P. Stonehouse
Net 12M change
-$4,136,189
Latest report
31 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Jon P. Stonehouse | Director | $14,204,190 | Median | 31 Aug 2026 | ||
| Charles K. Gayer | President and CCO | $5,248,732 | Mixed | 19 Dec 2025 | ||
| Alane P. Barnes | Chief Legal Officer | $3,822,706 | -$3,462,537 | -48% | Filing P/S | 13 May 2026 |
| Helen M. Thackray | Chief R&D Officer | $2,829,885 | Mixed | 31 Mar 2025 | ||
| Anthony Doyle | Chief Financial Officer | $2,792,437 | Mixed | 19 Dec 2024 | ||
| Ronald Dullinger | Chief Commercial Officer | $2,015,146 | Mixed | 01 Jan 2026 | ||
| Sandeep Menon | Chief R&D Officer | $1,953,069 | Mixed | 06 Apr 2026 | ||
| Babar Ghias | Chief Financial Officer | $1,862,091 | Mixed | 17 Dec 2025 | ||
| Yarlagadda S. Babu | Chief Discovery Officer | $1,806,173 | Mixed | 14 Nov 2022 | ||
| Vincent Milano | Director | $1,096,420 | Median | 31 Aug 2026 | ||
| Nancy J. Hutson | Director | $1,025,086 | Mixed | 12 Jun 2025 | ||
| Steven K. Galson | Director | $820,289 | Mixed | 11 Jun 2026 | ||
| Theresa Heggie | Director | $767,749 | -$504,823 | -40% | Mixed | 11 Jun 2026 |
| Alan G. Levin | Director | $757,458 | Mixed | 11 Jun 2026 | ||
| Robert Alexander Ingram | Director | $606,198 | Mixed | 28 Feb 2023 | ||
| Amy E. McKee | Director | $478,210 | -$100,285 | -17% | Median | 31 Aug 2026 |
| Steve Aselage | Director | $469,377 | Mixed | 12 Jun 2024 | ||
| Machelle Sanders | Director | $437,310 | -$68,544 | -14% | Mixed | 11 Jun 2026 |
| Kenneth B. Lee Jr. | Director | $416,621 | Mixed | 13 Jun 2023 | ||
| Steven Frank | Director | $367,470 | Median | 31 Aug 2026 |
Recent insider transactions for BIOCRYST PHARMACEUTICALS INC
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jon P. Stonehouse | BCRX | Common Stock | Award | 0.05% | 644 | 1,340,419 | 31 Aug 2026 | Direct | ||
| Vincent Milano | BCRX | Common Stock | Award | 1.07% | 1,159 | 109,642 | 31 Aug 2026 | Direct | ||
| Jill C. Milne | BCRX | Common Stock | Award | 4.03% | 1,288 | 33,226 | 31 Aug 2026 | Direct | ||
| Amy E. McKee | BCRX | Common Stock | Award | 1.37% | 644 | 47,821 | 31 Aug 2026 | Direct | ||
| Steven Frank | BCRX | Common Stock | Award | 3.63% | 1,288 | 36,747 | 31 Aug 2026 | Direct | ||
| Jill C. Milne | BCRX | Common Stock | Award | 91.9% | 15,294 | 31,938 | 11 Jun 2026 | Direct | ||
| Jill C. Milne | BCRX | Automatic Stock Option Grant | Award | 33,540 | 33,540 | 11 Jun 2026 | Direct | |||
| Steven K. Galson | BCRX | Common Stock | Award | 122.4% | 15,294 | 27,794 | 11 Jun 2026 | Direct | ||
| Steven K. Galson | BCRX | Automatic Stock Option Grant | Award | 33,540 | 33,540 | 11 Jun 2026 | Direct | |||
| Alan G. Levin | BCRX | Common Stock | Award | 23.8% | 15,294 | 79,565 | 11 Jun 2026 | Direct | ||
| Alan G. Levin | BCRX | Automatic Stock Option Grant | Award | 33,540 | 33,540 | 11 Jun 2026 | Direct | |||
| Steven Frank | BCRX | Common Stock | Award | 75.8% | 15,294 | 35,459 | 11 Jun 2026 | Direct | ||
| Steven Frank | BCRX | Automatic Stock Option Grant | Award | 33,540 | 33,540 | 11 Jun 2026 | Direct | |||
| Machelle Sanders | BCRX | Common Stock | Award | 49.9% | 15,294 | 45,936 | 11 Jun 2026 | Direct | ||
| Machelle Sanders | BCRX | Automatic Stock Option Grant | Award | 33,540 | 33,540 | 11 Jun 2026 | Direct | |||
| Vincent Milano | BCRX | Common Stock | Award | 16.4% | 15,294 | 108,483 | 11 Jun 2026 | Direct | ||
| Vincent Milano | BCRX | Automatic Stock Option Grant | Award | 33,540 | 33,540 | 11 Jun 2026 | Direct | |||
| Jon P. Stonehouse | BCRX | Common Stock | Award | 1.15% | 15,294 | 1,339,775 | 11 Jun 2026 | Direct | ||
| Jon P. Stonehouse | BCRX | Automatic Stock Option Grant | Award | 33,540 | 33,540 | 11 Jun 2026 | Direct | |||
| Amy E. McKee | BCRX | Common Stock | Award | 48% | 15,294 | 47,177 | 11 Jun 2026 | Direct | ||
| Amy E. McKee | BCRX | Automatic Stock Option Grant | Award | 33,540 | 33,540 | 11 Jun 2026 | Direct | |||
| Theresa Heggie | BCRX | Common Stock | Award | 23.4% | 15,294 | 80,646 | 11 Jun 2026 | Direct | ||
| Theresa Heggie | BCRX | Automatic Stock Option Grant | Award | 33,540 | 33,540 | 11 Jun 2026 | Direct | |||
| Jill C. Milne | BCRX | Common Stock | Award | 8.2% | 1,262 | 16,644 | 29 May 2026 | Direct | ||
| Jon P. Stonehouse | BCRX | Common Stock | Award | 0.05% | 631 | 1,324,481 | 29 May 2026 | Direct | ||
| Amy E. McKee | BCRX | Common Stock | Award | 2.02% | 631 | 31,883 | 29 May 2026 | Direct | ||
| Vincent Milano | BCRX | Common Stock | Award | 1.22% | 1,122 | 93,189 | 29 May 2026 | Direct | ||
| Steven Frank | BCRX | Common Stock | Award | 6.68% | 1,262 | 20,165 | 29 May 2026 | Direct | ||
| Amy E. McKee | BCRX | Common Stock | Sale | -26.4% | $100,285 | $8.97 | -11,180 | 31,252 | 18 May 2026 | Direct |
| Alane P. Barnes | BCRX | Common Stock | Sale | -13.5% | $596,250 | $9.54 | -62,500 | 400,703 | 13 May 2026 | Direct |
| Alane P. Barnes | BCRX | Common Stock | Options Exercise | 15.6% | 62,500 | 463,203 | 13 May 2026 | Direct | ||
| Alane P. Barnes | BCRX | Emp. Stock Option (Right to Buy) | Options Exercise | -100% | -62,500 | 0 | 13 May 2026 | Direct | ||
| Sandeep Menon | BCRX | Common Stock | Award | 205,150 | 205,150 | 06 Apr 2026 | Direct | |||
| Sandeep Menon | BCRX | Emp. Stock Option (Right to Buy) | Award | 441,350 | 441,350 | 06 Apr 2026 | Direct | |||
| Theresa Heggie | BCRX | Common Stock | Sale | -43.3% | $504,823 | $10.11 | -49,933 | 65,352 | 20 Mar 2026 | Direct |
| Theresa Heggie | BCRX | Common Stock | Options Exercise | 76.4% | 49,933 | 115,285 | 20 Mar 2026 | Direct | ||
| Theresa Heggie | BCRX | Automatic Stock Option Grant | Options Exercise | -100% | -49,933 | 0 | 20 Mar 2026 | Direct | ||
| Alane P. Barnes | BCRX | Common Stock | Sale | -27.2% | $1,372,500 | $9.15 | -150,000 | 400,703 | 16 Mar 2026 | Direct |
| Alane P. Barnes | BCRX | Common Stock | Options Exercise | 37.4% | 150,000 | 550,703 | 16 Mar 2026 | Direct | ||
| Alane P. Barnes | BCRX | Emp. Stock Option (Right to Buy) | Options Exercise | -100% | -150,000 | 0 | 16 Mar 2026 | Direct | ||
| Jon P. Stonehouse | BCRX | Common Stock | Disposed to Issuer | -18.8% | -305,995 | 1,323,850 | 02 Mar 2026 | Direct | ||
| Jon P. Stonehouse | BCRX | Common Stock | Options Exercise | 23.1% | 305,995 | 1,629,845 | 02 Mar 2026 | Direct | ||
| Jon P. Stonehouse | BCRX | Emp. Stock Option (Right to Buy) | Options Exercise | -100% | -305,995 | 0 | 02 Mar 2026 | Direct | ||
| Jill C. Milne | BCRX | Common Stock | Award | 3.55% | 528 | 15,382 | 27 Feb 2026 | Direct | ||
| Jon P. Stonehouse | BCRX | Common Stock | Award | 0.03% | 421 | 1,323,850 | 27 Feb 2026 | Direct | ||
| Vincent Milano | BCRX | Common Stock | Award | 0.93% | 848 | 92,067 | 27 Feb 2026 | Direct | ||
| Steven Frank | BCRX | Common Stock | Award | 7.29% | 1,285 | 18,903 | 27 Feb 2026 | Direct | ||
| Amy E. McKee | BCRX | Common Stock | Award | 1.54% | 642 | 42,432 | 27 Feb 2026 | Direct | ||
| Jill C. Milne | BCRX | Common Stock | Award | 14,854 | 14,854 | 23 Jan 2026 | Direct | |||
| Jill C. Milne | BCRX | Automatic Stock Option Grant | Award | 26,684 | 26,684 | 23 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.